Impact of preemptive therapy for Cytomegalovirus on hospitalizations and cost after Hematopoietic Stem Cell Transplantation

Cytomegalovirus (CMV) infection is the most common clinically significant viral infection among CMV seropositive (R+) recipients of allogeneic hematopoietic cell transplant (HCT) [1]. CMV is associated with substantial morbidity and mortality, particularly in recipients of T-cell depleted (TCD) allografts and human leukocyte antigen (HLA)-mismatched or unrelated donor allografts [2-4]. The pre-emptive therapy (PET) approach is broadly used for CMV management [1]. In this approach, HCT recipients are routinely monitored for CMV post HCT and anti-viral therapy is initiated upon detection of CMV infection.

Source: Biology of Blood and Marrow Transplantation - July 3, 2020 Category: Hematology Authors: Jiaqi Fang, Yiqi Su, Phaedon D. Zavras, Amit D. Raval, Yuexin Tang, Miguel-Angel Perales, Sergio Giralt, Anat Stern, Genovefa A. Papanicolaou Source Type: research